Global state: Not improved or worsened ‐ medium term Dichotomised Montgomery‐Asberg Depression Rating Scale (MDRS) · patients with schizophrenia
It is very uncertain whether ORAL FLUPHENAZINE changes global state: Not improved or worsened ‐ medium termDichotomised… compared with PLACEBO (very low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
It is very uncertain whether ORAL FLUPHENAZINE changes global state: Relapse ‐ long termClinical judgement compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects: Death ‐ long termOccurrences of death · patients with schizophrenia
ORAL FLUPHENAZINE showed no clear difference in adverse effects: Death ‐ long termOccurrences of death compared with PLACEBO (low certainty).
1 finding from 1 review
Adverse effects: 2. Extrapyramidal ‐ akathisia · patients with schizophrenia
ORAL FLUPHENAZINE probably leads to higher adverse effects: Extrapyramidal effects (akathisia) ‐ short… compared with PLACEBO (moderate certainty).
1 finding from 1 review
Adverse effects: extrapyramidal adverse effectsParkinsonism (rigidity) short term (< 3 months) Clinical diagnoses · patients with schizophrenia
ORAL FLUPHENAZINE probably leads to higher adverse effects: Extrapyramidal effects (rigidity) ‐ short… compared with PLACEBO (moderate certainty).
1 finding from 1 review
Mental state · patients with schizophrenia
1 finding from 1 review
Clinically important change in life skills (long term) ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (long term) ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effect: extrapyramidal symptoms ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ inefficacy short term (up to 12 weeks) compared with RISPERIDONE (very low certainty).
1 finding from 1 review
Cost‐effectiveness (long term) ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically important response (defined by study) ‐ short term (up to 12 weeks) decreased rate of BPRS score < 20% · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes clinically important response (defined by study) ‐ short term (up to… compared with QUETIAPINE (very low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically important change in life skills (long term) · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (long term) · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ inefficacy ‐ short term (up to 12 weeks) compared with QUETIAPINE (very low certainty).
1 finding from 1 review
Cost‐effectiveness · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically important response (defined by study) ‐ short term (up to 12 weeks) decreased rate of PANSS score < 40%, decreased rate of BPRS score < 40% · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes clinically important response (defined by study) ‐ short term (up to… compared with OLANZAPINE (very low certainty).
1 finding from 1 review